Protective effects of genistein in homocysteine-induced endothelial cell inflammatory injury

Molecular and Cellular Biochemistry

Volumn 403, Issue 1-2, 2015, Pages 43-49

  Han, Shengbo ^a   Wu, Hui ^b   Li, Wenxue ^c   Gao, Pan ^a  

^a Zhengzhou Hospital of Traditional Chinese Medicine   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c Department of Psychology   (China)

Author keywords

Cytokine; Genistein; Homocysteine; Inflammatory injury; ROS

Indexed keywords

GENISTEIN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA;

CELL LINE; CELL SHAPE; CELL SURVIVAL; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE; CELL SHAPE; CELL SURVIVAL; GENISTEIN; HOMOCYSTEINE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; PROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR RELA;

EID: 84939988250     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2335-0     Document Type: Article

References (42)

1. Chen F, Castranova V, Li Z et al (2003) Inhibitor of nuclear factor kappaB kinase deficiency enhances oxidative stress and prolongs c-Jun NH2-terminal kinase activation induced by arsenic. Cancer Res 63:7689–7693
2. Yang G, Abate A, George AG et al (2004) Maturational differences in lung NF-κB activation and their role in tolerance to hyperoxia. Clin Invest 114:669–678
3. Lemarie A, Morzadec C, Delphine M et al (2006) Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kB related survival pathway down-regulation. J Pharmacol Exp Ther 316:304–314
4. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115–126
5. Pearson TA, Mensah GA, Alexander RW et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511
6. McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56:111–128
7. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefts of increasing folic acid intakes. JAMA 274:1049–1057
8. Nygard O, Vollset SE, Refsum H et al (1995) Total plasma homocysteine and cardiovascular risk profile. The Hordaland HCY Study. JAMA 274:1526–1533
9. Ueland PM, Refsum H, Beresford SA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324–332
10. Tehlivets O (2011) Homocysteine as a risk factor for atherosclerosis: is its conversion to s-adenosyl-L-homocysteine the key to deregulated lipid metabolism? J Lipids 2011:702853
11. Dong D, Wang B, Yin W et al (2013) Disturbance of copper homeostasis is a mechanism for homocysteine-induced vascular endothelial cell injury. PLoS One 8:e76209
12. Clarke M, Bennett M, Littlewood T (2007) Cell death in the cardiovascular system. Heart 93:659–664
13. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European concerted action on thrombosis and disabilities angina pectoris study group. N Engl J Med 332:635–641
14. Danesh J, Wheeler JG, Hirschfield GM et al (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350:1387–1397
15. Ridker PM, Hennekens CH, Buring JE, Rifai N (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342:836–843
16. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M (2009) Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 16:94–112
17. Srinivasan S, Bolick DT, Hatley ME et al (2004) Glucose regulates interleukin- 8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem 279:31930–31936
18. Morigi M, Angioletti S, Imberti B et al (1998) Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. J Clin Invest 101:1905–1915
19. Srinivasan S, Yeh M, Danziger EC et al (2003) Glucose regulates monocyte adhesion through endothelial production of interleukin-8. Circ Res 92:371–377
20. Exner M, Hermann M, Hofbauer R et al (2001) Genistein prevents the glucose autoxidation mediated atherogenic modification of low density lipoprotein. Free Radic Res 34:101–112
21. Fotsis T, Pepper M, Adlercreutz H et al (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90:2690–2694
22. Kiriakidis S, Högemeier O, Starcke S et al (2005) Novel tempeh (fermented soya bean) isoflavones inhibit in vivo angiogenesis in the chicken chorioallantoic membrane assay. Br J Nutr 93:317–323
23. Kayisli UA et al (2013) Genistein inhibits cell proliferation and stimulates apoptosis in human coronary artery endothelial cells. Gynecol Obstet Invest 75:235–242
24. Babu PV, Si H, Fu Z, Zhen W, Liu D (2012) Genistein prevents hyperglycemia-induced monocyte adhesion to human aortic endothelial cells through preservation of the cAMP signaling pathway and ameliorates vascular inflammation in obese diabetic mice. J Nutr 142:724–730
25. Homeister JW, Willis (2010) Atherosclerosis: pathogenesis, genetics and experimental models. Encyclopedia of life sciences. John Wiley, Sons Ltd, Chichester
26. Hofmann MA, Lalla E, Lu Y et al (2001) Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine mode. Clin Invest 107:675–683
27. Plazar N, Jurdana M (2012) Hyperhomocysteinemia: relation to cardiovascular disease and venous thromboembolism. In: Abdelaal MA (ed) Pathophysiology and clinical aspects of venous thromboembolism in neonates, renal disease and cancer patients. InTech, Rijeka, pp 17–34
28. Edirimanne VE, Woo CW, Siow YL et al (2007) Homocysteine stimulates NADPH oxidase-mediated superoxide production leading to endothelial dysfunctionin rats. Can J Physiol Pharmacol 85:1236–1247
29. Weiss N (2005) Mechanisms of increased vascular oxidant stress in hyperhomocysteinemia and its impact on endothelial function. Curr Drug Metab 6:27–36
30. Cortes Magdalena P, Juan P (2013) Inhibition of ATP-induced calcium influx by homocysteine in human umbilical vein endothelial cells. Cell Biol Int 37:600–607
31. Tyagi N, Sedoris KC, Steed M et al (2005) Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 289:H2649–H2656
32. Zhang T, Wang F, Xu HX et al (2012) Activation of nuclear factor erythroid 2-related factor 2 and PPARg plays a role in the genistein-mediated attenuation of oxidative stress-induced endothelial cell injury. Br J Nutr 2:1–13
33. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH (2006) Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. Cancer Res 66:10553–10559
34. Li Y, Sarkar FH (2002) Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin Cancer Res 8:2369–2377
35. Manach C, Williamson G, Morand C, Scalbert A (2005) Re´me´sy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S–242S
36. Williamson G, Manach C (2005) Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 81:243S–255S
37. Banerjee S, Li Y, Wang Z, Sarkar FH (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett 269:226–242
38. Polkowski K, Mazurek AP (2000) Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 57:135–155
39. King RA, Bursill DB (1998) Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67:867–872
40. Cassidy A, Faughnan M (2000) Phyto-oestrogens through the life cycle. Proc Nutr Soc 59:489–496
41. Jia Z, Babu PV, Si H et al (2013) Genistein inhibits TNF-α-induced endothelial inflammation through the protein kinase pathway A and improves vascular inflammation in C57BL/6 mice. Int J Cardiol 168:2637–2645
42. Fuchs D, Erhard P, Rimbach G et al (2005) Genistein blocks homocysteine-induced alterations in the proteome of human endothelial cells. Proteomics 5:2808–2818